Previous Article | Next Article 
Infection and Immunity, May 2000, p. 2713-2719, Vol. 68, No. 5
0019-9567/00/$04.00+0
Host Resistance and Immune Deviation in Pigeon Cytochrome
c T-Cell Receptor Transgenic Mice Infected with
Toxoplasma gondii
Carmen M.
Collazo,1,*
Carla
Miller,2,
George
Yap,1
Sara
Hieny,1
Patricia
Caspar,1
Ronald H.
Schwartz,2 and
Alan
Sher1
Immunobiology Section, Laboratory of
Parasitic Diseases,1 and Laboratory of
Cellular and Molecular Immunology,2 National
Institute of Allergy and Infectious Diseases, National Institutes of
Health, Bethesda, Maryland 20892
Received 25 October 1999/Returned for modification 15 December
1999/Accepted 17 February 2000
 |
ABSTRACT |
Resistance to Toxoplasma gondii has been shown to be
mediated by gamma interferon (IFN-
) produced by NK,
CD4+, and CD8+ T cells. While studies of SCID
mice have implicated NK cells as the source of the cytokine in acute
infection, several lines of evidence suggest that IFN-
production by
CD4+ T lymphocytes also plays an important role in
controlling early parasite growth. To evaluate whether this function is
due to nonspecific as opposed to T-cell receptor (TCR)-dependent
stimulation by the parasite, we have examined the resistance to
T. gondii infection of pigeon cytochrome c
transgenic (PCC-Tg) Rag-2
/
mice in which all
CD4+ T lymphocytes are unreactive with the protozoan. When
inoculated with the ME49 strain, PCC-Tg animals exhibited only
temporary control of acute infection and succumbed by day 17. Intracellular cytokine staining by flow cytometry revealed that, in
contrast to infected nontransgenic controls, infected PCC-Tg animals
failed to develop IFN-
-producing CD4+ T cells. Moreover,
the CD4+ lymphocytes from these mice showed no evidence of
activation as judged by lack of upregulated expression of CD44 or CD69.
Nevertheless, when acutely infected transgenic mice were primed by PCC
injection, the lymphokine responses measured after in vitro antigen
restimulation displayed a strong Th1 bias which was shown to be
dependent on endogenous interleukin 12 (IL-12). The above findings
argue that, while T. gondii-induced IL-12 cannot trigger
IFN-
production by CD4+ T cells in the absence of TCR
ligation, the pathogen is able to nonspecifically promote Th1 responses
against nonparasite antigens, an effect that may explain the
immunostimulatory properties of T. gondii infection.
 |
INTRODUCTION |
Toxoplasma gondii is an
intracellular protozoan that is readily controlled by the host
cell-mediated immune response resulting in a chronic infection
maintained by dormant parasite cysts. Host resistance to the parasite
occurs in two major phases. In the initial acute phase, growth of the
replicative tachyzoite stage is curbed by an interleukin 12 (IL-12)-dependent gamma interferon (IFN-
) response that appears to
involve elements of the innate immune system. In the second, adaptive
phase, IFN-
produced by sensitized CD4+ and
CD8+ T lymphocytes completes the clearance of tachyzoites
from host tissues and prevents reactivation of chronic infection from
the resulting cysts (reviewed in references 3 and
10).
It is generally assumed that NK cells are the major source of the
IFN-
that controls initial parasite replication during the first
week of acute infection. Thus, T-lymphocyte-deficient SCID mice survive
for 14 to 16 days following infection with the avirulent ME49 strain
but succumb after only 8 to 9 days when simultaneously treated with
neutralizing anti-IFN-
monoclonal antibody (MAb) (5, 9).
Nevertheless, evidence also exists suggesting that CD4+
and, to a lesser extent, CD8+ T cells contribute to
IFN-
-mediated host resistance during this early acute phase of the
infection. Thus, infected T- and B-cell-deficient Rag mice produce only
20% of the level of serum IFN-
displayed by infected
T-cell-sufficient control animals at the same 5-day (d) time point (G. Yap, unpublished observations). In addition, in vitro CD4+
T-cell depletion partially ablates IFN-
production by spleen cells
from 5-d infected mice, and sorted CD4+ T lymphocytes from
the same animals synthesized high levels of the cytokine while much
lower amounts were secreted by sorted CD8+ T cells
(6). Finally, common cytokine receptor
-chain
(
c) knockout (KO) mice, which lack functional NK and
CD8+ T cells, have been shown to develop IFN-
-dependent,
CD4+ T-cell-mediated control of acute infection and survive
into the chronic phase (17).
Although these observations support a role for CD4+ T
lymphocytes in early resistance to T. gondii, the mechanism
by which a major IFN-
response is induced in these cells so rapidly
(i.e., within 5 d) after host infection is unclear. One
possibility is that the IL-12 burst occurring soon after host invasion
nonspecifically triggers IFN-
production from naive CD4+
T cells in a manner analogous to its induction of the latter cytokine
from NK cells. Such a direct effect of IL-12 on IFN-
production by
human CD4+ T cells has previously been reported
(25). That T. gondii nonspecifically promotes
CD4+ T-cell function is also suggested by numerous studies
demonstrating immunopotentiating effects of the parasite on the
induction of cell-mediated immunity to unrelated pathogens and tumors
(8, 13, 16).
In the present report, we have studied the influence of T. gondii infection on CD4+ T-cell activation and
effector function in an attempt to better define the role played by
these cells in the clearance of acute infection as well as the
mechanisms underlying the induction of nonspecific immunity by the
parasite. Our approach was to analyze host resistance and
CD4+ T-cell responses in T-cell receptor (TCR) transgenic
mice that recognize pigeon cytochrome c (PCC) peptide 81-104 in association with the I-Ea class II molecule
(14, 20). All of the CD4+ T cells in these
animals are specific for PCC since the mice were backcrossed onto a
Rag-2
/
background which prevents new TCR species from
being generated by endogenous V gene rearrangement. Furthermore, as
shown below, this receptor does not cross-react with tachyzoite antigen
(Ag). Therefore, any CD4+ T-cell responses elicited by
T. gondii infection must arise nonspecifically rather than
as a result of Ag-mediated TCR ligation. The results of our experiments
in this model argue against a nonspecific mechanism of IFN-
induction from CD4+ T lymphocytes during acute infection
while formally demonstrating a role for the parasite in biasing
bystander CD4+ T-cell responses toward a Th1 phenotype.
 |
MATERIALS AND METHODS |
Experimental animals.
C57BL/6 TCR-Cyt-5C.C7-1 transgenic
mice (14, 20) were cesarean rederived and backcrossed for
multiple generations with B10.A/SgSnAi animals in the National
Institute of Allergy and Infectious Diseases (NIAID) contract facility
at Taconic Farms, Inc. (Germantown, N.Y.). They were then bred with
B10.D2 Rag-2
/
mice to introduce the
Rag-2
/
mutation and made homozygous for B10.A,
Rag-2
/
, and the TCR transgene. This strain is referred
to as B10.A/SgSnAi TCR Cyt-5C.C7-1, Rag-2
/
, and was
supplied by the NIAID-Taconic exchange contract. Control B10.A/SgSnAi
and B10.A/Ai Rag-2
/
mice were also obtained from the
NIAID-Taconic contract facility. B10.A/SgSnJ mice purchased from the
Jackson Laboratory (Bar Harbor, Maine) were used in some studies.
Animals were sex and age matched for each experiment.
T. gondii infections, parasites, and parasite Ag
preparation.
A cyst suspension of the avirulent ME49 strain of
T. gondii was prepared from brains of infected C57BL/6 mice
as described previously (18). For experimental infections,
mice received 20 cysts in 0.5 ml of phosphate-buffered saline (PBS)
intraperitoneally (i.p.). The RH strain of T. gondii was
maintained by culturing the parasites at 37°C in human foreskin
fibroblast monolayers. Soluble tachyzoite Ag (STAg) was prepared from
sonicated RH parasites as previously described (7).
In vitro T-cell response assays.
Single-cell suspensions
were prepared from homogenized spleens, and erythrocytes were removed
using ACK lysing buffer (Bio Whittaker, Walkersville, Md.). Spleen
cells were cultured at 3 × 105 or 1 × 105 cells per well (see figure legends for specific
details) in flat-bottomed 96-well plates in 200 µl of RPMI 1640 medium (Life Technologies, Grand Island, N.Y.) supplemented with 10%
fetal bovine serum, 100 U of penicillin per ml, 100 µg of
streptomycin per ml, 2 mM L-glutamine, 10 mM HEPES, and
5 × 10
5 M 2-mercaptoethanol. When 105
spleen cells per well were used, they were cultured with 5 × 105 irradiated (3,000-R) T-cell-depleted B10.A spleen cells
as antigen-presenting cells (APC) (11). Spleen cell cultures
were stimulated in vitro with 10 µg of STAg per ml, 10 µg of
plate-bound anti-CD3 (PharMingen, San Diego, Calif.) per ml, 1 µM PCC
peptide (amino acids 81 to 104, synthesized in the peptide synthesis
facility, NIAID, National Institutes of Health), or live irradiated
(15,000-R) tachyzoites (cell/tachyzoite ratio = 10:1). Culture
supernatants were collected at 48 h for determination of IFN-
using a previously published enzyme-linked immunosorbent assay (ELISA)
protocol (19). IL-4 levels were measured in the same
supernatants using a commercial ELISA kit (Endogen, Woburn, Mass.). For
T-cell proliferation assays, cells were pulsed with 1 µCi of
[3H]thymidine (ICN Pharmaceuticals, Inc., Costa Mesa,
Calif.) after 48 h in culture and harvested 18 h later onto
glass-fiber filters using a 96-well cell harvester (Brandel,
Gaithersburg, Md.). Incorporated [3H]thymidine was
measured by scintillation counting in a Betaplate 1205 detector
(Wallac, Gaithersburg, Md.).
Fluorescence-activated cell sorting (FACS) analysis of lymphoid
cell populations.
Total spleen cells (106) were
stained using anti-CD4 phycoerythrin (PE)- or Cy-Chrome-labeled rat MAb
RM4-5, anti-CD8
fluorescein isothiocyanate (FITC)-conjugated rat MAb
53-6.7, anti-NK1.1 PE-labeled mouse MAb PK136, anti-CD44
FITC-conjugated rat MAb IM7, or anti-CD69 FITC-conjugated hamster MAb
H1.2F3, all purchased from PharMingen. Prior to specific labeling with
antibodies, Fc receptors were blocked with anti-CD16/32 (clone 2.4G2;
PharMingen). Flow cytometric analysis was performed on a
FACScalibur instrument (Becton Dickinson, San Jose, Calif.) using
CellQuest software. Cells were gated on CD4+ for
measurement of CD44 and CD69 expression.
In vivo CD4, IFN-
, and IL-12 depletion.
For IFN-
depletion, mice were injected i.p. with 1 mg of anti-IFN-
MAb XMG6
(rat immunoglobulin G1 [IgG1]; cell line provided by R. Coffman,
DNAX, Palo Alto, Calif.) 1 day before as well as on the day of
infection with ME49. Depletion of CD4+ T cells was achieved
by treating mice i.p. with 1 mg of GK1.5 MAb (4) 2 days
before and on the day of parasite challenge. Injection of animals with
MAb was continued on every third day, and survival was monitored. In
some experiments involving PCC immunization, animals received an i.p.
injection of 1 mg of anti-IL-12 p40 MAb C17.8 (rat IgG2a; cell line was
a gift from G. Trinchieri, Wistar Institute, Philadelphia, Pa.) 1 day
before, on the day of, and 3 days after Ag administration. Control mice
were given the same dosage of a rat IgG1 MAb (GL113 MAb) specific for
-galactosidase.
Quantitation of IFN-
-producing cells by intracellular
staining.
Intracellular IFN-
staining was performed as
described previously (21) with minor modifications. Briefly,
spleen cells from uninfected and ME49-infected wild-type (WT) and TCR
transgenic animals were cultured in complete RPMI medium and stimulated
with plate-bound anti-mouse CD3
MAb (clone 145-2C11; PharMingen)
at 10 µg/ml for 2.5 h. Brefeldin A (Sigma Chemical Co., St.
Louis, Mo.) was added at this time at a final concentration of 10 µg/ml to prevent protein secretion, and the cultures were incubated for an additional 3.5 h. Cells were harvested and stained using anti-CD4 FITC-labeled rat MAb RM4-5 (PharMingen). After fixation in
2% paraformaldehyde, cells were permeabilized in buffer containing 0.1% saponin and restained using PE-conjugated rat anti-mouse IFN-
(clone XMG1.2; PharMingen) or PE-conjugated rat IgG1 isotype control
(clone R3-34; PharMingen). At least 100,000 events were acquired on a
FACScalibur, and the data were analyzed using CellQuest software.
Measurement of in vivo responses to PCC in T. gondii-infected transgenic mice.
TCR transgenic mice were
infected with 20 cysts of the avirulent ME49 strain of T. gondii via the i.p. route as described above. Five days after
infection, mice were injected i.p. with 100 µl of a PBS suspension
containing 50 µg of PCC (Sigma Chemical Co.) precipitated in alum or
with 100 µl of PBS alone. Animals were sacrificed 5 d after PCC
injection, and spleen cells were analyzed for surface markers by FACS
and for in vitro production of IFN-
and IL-4 after restimulation
with Ag.
Statistical analyses.
Student's t test was used
to evaluate the statistical significance of differences between data points.
 |
RESULTS |
T lymphocytes from PCC TCR transgenic mice fail to cross-react with
tachyzoite Ag.
To make certain that the CD4+ T cells
in PCC TCR transgenic mice fail to react with T. gondii and
therefore should not respond specifically during parasite infection,
spleen cells from uninfected transgenic mice were exposed in vitro to
live irradiated tachyzoites, a soluble tachyzoite extract (STAg), or
PCC as a positive control. As expected, these cell populations
responded vigorously to PCC as assessed by both in vitro thymidine
incorporation and IFN-
production while failing to react
significantly by either assay with live parasites or STAg (Fig.
1). On the basis of the above findings,
we concluded that any CD4+ T-cell responses observed during
infection of transgenic mice with T. gondii are unlikely to
result from conventional activation through TCR ligation.

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 1.
T cells from TCR transgenic mice do not proliferate (A)
or produce IFN- (B) in response to T. gondii antigens.
Spleen cells from uninfected TCR transgenic mice were cultured in
duplicate at 3 × 105 cells/well in the presence of
PCC peptide (1 µM; amino acids 81 to 104), STAg (10 µg/ml), or live
irradiated RH (3 × 104 tachyzoites/well). An aliquot
of each culture supernatant was taken to analyze IFN- production by
ELISA after 48 h of incubation, and proliferation was determined
by measuring incorporation of [3H]thymidine (1 µCi/well) added to the cultures for another 18 h. Change in
counts per minute ( cpm) was then calculated by subtracting the
incorporation obtained with unstimulated cultures (320 ± 15 cpm).
Results are expressed as the means ± standard deviations of the
averaged duplicate values determined for two mice per group. The modest
IFN- response to STAg was not observed in three repeat experiments
and is likely to reflect low-level IL-12-induced production of the
cytokine from splenic NK cells (6) since similar levels were
occasionally seen with nontransgenic B10.A control animals and
FACS-sorted CD4+ T cells (99% pure) gave no response to
STAg in the presence of irradiated B10.A APC (data not shown).
Infection of the mice with T. gondii failed to increase
these background responses to parasite Ag (data not shown).
|
|
FACS analysis of spleen cells was performed to compare the levels of
cells (CD4
+, CD8
+, and NK1.1
+)
potentially responsive to
T. gondii in transgenic compared
with
WT hosts. As shown in Fig.
2,
comparable numbers of splenic CD4
+ T cells were observed in
the transgenic and WT mice both before
and 5 d after infection
with the ME49 strain of
T. gondii despite
the difference in
TCR specificity. In contrast, as expected from
the major
histocompatibility complex class II restriction of the
PCC-specific
TCR, the spleens from the transgenic mice were deficient
in
CD8
+ T cells both before and after infection.
NK1.1
+ cells, on the other hand, were present in spleens
from both types
of animals, although in somewhat lower numbers in the
transgenic
population after infection.

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 2.
TCR transgenic and control B10.A mice have similar
numbers of splenic CD4+ and NK1.1+ cells pre-
and postinfection. Spleen cells from uninfected (A) and 5-d
ME49-infected (B) WT control animals (gray bars) or TCR transgenic mice
(black bars) were stained for CD4, CD8, and NK1.1 expression using
directly conjugated antibodies. The total numbers of CD4+,
CD8+, and NK1.1+ cells were determined by
multiplying the percentages of these cell populations by the total
number of spleen cells. Values represent the means ± standard
errors of the means of five mice per group.
|
|
Transgenic mice exhibit partial control of acute but not chronic
T. gondii infection.
In order to assess their
resistance to T. gondii, transgenic mice as well as B10.A
Rag-2
/
and B10.A WT control animals were infected i.p.
with 20 cysts of the ME49 strain and survival was monitored for a
period of 30 days. As shown in Fig. 3,
the transgenic mice succumbed to the infection between 12 and 21 d
postinoculation. This survival pattern was identical to that displayed
by the simultaneously infected B10.A Rag-2
/
control
animals and yet clearly distinct from the mortality curve previously
described for IFN-
KO mice (18), which are highly susceptible to acute infection (Fig. 3A). Priming the TCR transgenic mice with PCC (50 µg) in alum 5 d before infection failed to
increase the survival time of the animals (data not shown). The latter observation further argues against the ability of T. gondii
to nonspecifically activate PCC-specific T cells into effectors.

View larger version (17K):
[in this window]
[in a new window]
|
FIG. 3.
Survival of TCR transgenic versus control mice following
T. gondii infection. Mice were infected i.p. with 20 cysts
of the ME49 strain, and survival was monitored over a period of 30 d. (A) Survival of infected TCR transgenic animals (closed circles) and
B10.A Rag-2 / mice (open circles) compared with
literature values (18) for ME49-infected IFN- KO animals
(dashed line). (B) Mortality of infected B10.A control mice obtained
from either the Jackson Laboratory (straight line) or Taconic Farms
(dashed line with triangles) and TCR transgenic animals (closed
circles; same data as shown in panel A). (C) Survival of infected TCR
transgenic mice treated with neutralizing MAb to IFN- (closed
triangles), anti-CD4 MAb (open squares), or control (GL113) MAb (closed
squares). Effective depletion of the CD4+ cell population
was assessed by flow cytometric analysis of whole blood using a
PE-conjugated anti-CD4 MAb. Experimental groups consisted of 6 to 20 mice each. Each of the three experiments shown was repeated at least
once with similar results.
|
|
B10.A WT mice have been reported to be resistant to ME49 infection as
judged by both survival and the low numbers of brain
cysts recovered
during the chronic phase (
1). Surprisingly,
most of the
B10.A mice used as controls for our mortality experiments
succumbed,
dying 4 to 5 d later than the TCR transgenic animals
constructed
on the same background. This enhanced susceptibility
proved to be a
feature of B10.A mice derived from the NIAID contract
at Taconic Farms
(the source of both the WT and transgenic animals),
since B10.A mice
obtained from the Jackson Laboratory, as predicted
from the previous
studies, were highly resistant to the same infection
(Fig.
3B).
Interestingly, the unexpected early death of the Taconic
B10.A WT mice
was not the result of impaired control of infection,
since these
animals showed the same low level of cyst burden (56
± 25 cysts/brain) at day 15 as did the corresponding B10.A animals
from the
Jackson Laboratory (70 ± 18). Nonetheless, the Taconic-derived
TCR transgenic mice were clearly defective in host resistance
as judged
by their elevated cyst counts (1,617 ± 416;
P = 0.002
versus recovery from B10.A mice from Taconic), which were
comparable
to those determined (1,844 ± 305) for simultaneously
infected
B10.A Rag-2
/
mice (also purchased from Taconic
Farms).
Since the TCR transgenic mice were found to be more resistant than
IFN-

KO animals but equivalent to, if not more susceptible
than,
T-cell-deficient Rag-2
/
mice, these observations
suggested that the PCC-specific T cells
in the former animals are
unable to nonspecifically mediate IFN-

-dependent
control of
infection. In support of this conclusion, transgenic
mice depleted of
CD4
+ T lymphocytes by MAb treatment displayed the same
susceptibility
to infection as did transgenic animals treated with
control MAb
(Fig.
3C). Nevertheless, the transgenic mice were clearly
partially
resistant to infection since they succumbed earlier when
treated
with anti-IFN-

MAb (Fig.
3C). This partial resistance is
presumably
mediated by the IFN-

produced by the significant although
reduced
numbers of NK cells in the transgenic
animals.
CD4+ T cells in transgenic mice are not nonspecifically
triggered by T. gondii to produce IFN-
.
While the
transgenic CD4+ T cells clearly do not contribute to host
resistance, it remained possible that they are nonspecifically triggered to produce IFN-
. In order to examine this issue directly, intracellular staining for the cytokine was performed on spleen cells
obtained from WT and transgenic animals 7 d after ME49 infection. As shown in Fig. 4, 51% (7.2 of 14.1) of
the CD4+ cells in the infected B10.A control mice stained
positively for IFN-
, while only 0.2% of the corresponding
CD4+ cells from the PCC transgenic animals reacted
positively with the same antibody. Nevertheless, the infected
transgenic animals did develop significant levels of serum IFN-
(1.8 ± 0.25 versus 0 ng/ml in uninfected mice), reflecting their
early control of acute infection. Importantly, this early IFN-
response was not reduced as a result of in vivo anti-CD4 depletion,
arguing against the transgenic T cells as the source of the cytokine
(data not shown).

View larger version (29K):
[in this window]
[in a new window]
|
FIG. 4.
Intracellular flow cytometric analysis of IFN-
production by CD4+ T cells. Spleen cells from 7-d infected
B10.A control and TCR transgenic (TCR Tg) mice were stimulated in vitro
with anti-CD3 for 6 h and treated with brefeldin A added for the
last 2.5 h of the incubation. The splenocytes were then stained
with anti-CD4 MAb, fixed, permeabilized, and subsequently restained
with anti-IFN- MAb as described in Materials and Methods.
Splenocytes from uninfected mice and cells stained with isotype control
MAb failed to give significant staining in this assay (data not shown).
Similar results were obtained in a second experiment.
|
|
T. gondii infection fails to alter the activation
status of CD4+ T cells in PCC-immunized transgenic
mice.
Although the above findings clearly indicate that T. gondii cannot nonspecifically trigger IFN-
production in
CD4+ T cells, it was still possible that infection with the
protozoan enhances or biases T-cell responses initiated against
nonparasite Ag consistent with its previously reported adjuvant
effects. As a first step in investigating this hypothesis, we examined
the effect of T. gondii infection on the activation status
of transgenic CD4+ cells primed in vivo with PCC. In this
experiment, mice were given 50 µg of PCC i.p. 5 d after ME49
infection and spleen cells were recovered 2 d later for analysis
of CD69 and 5 d later for measurement of CD44. As shown in Fig.
5, in control animals not given PCC,
T. gondii infection failed to elevate the expression of
either activation marker on CD4+ T cells. This observation
provides further evidence against nonspecific triggering of the
transgenic cells by the parasite. Similarly, in PCC-primed mice, where
activation was clearly visible, the presence of T. gondii
infection did not result in altered CD69 or CD44 expression. Thus,
Toxoplasma does not appear to nonspecifically augment or
suppress CD4+ T-cell activation as judged by these markers.

View larger version (38K):
[in this window]
[in a new window]
|
FIG. 5.
T. gondii infection fails to result in
upregulated expression of CD69 and CD44 on CD4+ T cells
from PCC transgenic mice. PCC protein was administered i.p. 5 d
after ME49 infection of TCR transgenic mice. Splenocytes were analyzed
by FACS 2 d later for CD69 expression (A) and 5 d later for
CD44 expression (B). The analysis was performed after gating on
CD4+ cells. Control PCC transgenic animals received PBS,
T. gondii, or PCC alone as indicated in the histograms. The
experiment shown is representative of three performed.
|
|
T. gondii infection results in Th1-biased PCC-induced
cytokine production in transgenic mice.
One possible explanation
of the adjuvant effects of T. gondii infection on
cell-mediated immune responses is that the parasite promotes, by a
bystander effect, the differentiation of Th1 cells. To test this
hypothesis, we analyzed the influence of ME49 infection on PCC-induced
cytokine production in transgenic mice primed with the Ag in alum
5 d after parasite inoculation and sacrificed 5 d later.
Spleen cells were then stimulated with PCC in vitro, and the levels of
the signature cytokines IL-4 and IFN-
were measured in culture
supernatants by ELISA 48 h later. As shown in Fig.
6, uninfected transgenic mice primed with
PCC developed Ag-induced cytokine responses characterized by elevated
IL-4 as well as IFN-
compared with control mice injected with PBS
alone. In striking contrast, when the same PCC transgenic mice were
infected with T. gondii, the PCC-induced cytokine production
profile was markedly skewed toward Th1 as judged by a greater than
threefold increase in IFN-
levels and no increase in IL-4 above
background levels. As expected, T. gondii infection alone
failed to trigger significant IL-4 and IFN-
responses in the
transgenic animals.

View larger version (13K):
[in this window]
[in a new window]
|
FIG. 6.
IL-4 and IFN- production by spleen cells from
PCC-immunized TCR transgenic mice infected with T. gondii.
ME49-infected TCR transgenic mice were injected i.p. with PCC protein
(50 µg) in alum 5 d after parasite inoculation. One group of
animals received neutralizing anti-IL-12 MAb on d 1, d 0, and d 3 after PCC administration. Mice were sacrificed on d 5 following PCC
injection, and spleen cells (105 cells/well) were incubated
in duplicate with T-cell-depleted irradiated spleen cells as APC
(5 × 105 cells/well) in the presence of 1 µM PCC
peptide (amino acids 81 to 104). Supernatants were harvested 48 h
later for determination of IL-4 and IFN- levels by ELISA, and the
average value for each mouse was calculated from the duplicate
cultures. Data shown indicate the means ± standard errors of the
means of pooled values from three experiments each involving three to
five animals. The effect of T. gondii infection on
PCC-induced IFN- and IL-4 responses was highly significant as
calculated by Student's t test (IL-4, P = 0.01; IFN- , P = 0.00005), as was the effect of
anti-IL-12 treatment on the PCC-induced IFN- response in T. gondii-infected mice (P = 0.0003).
|
|
T. gondii is known to induce high levels of IL-12 during
early infection. In order to analyze whether the production of this
proinflammatory cytokine plays a significant role in biasing the
PCC-stimulated lymphokine pattern toward a Th1 response, infected
transgenic mice were given neutralizing anti-IL-12 MAb on d

1,
0, and
d +3 following PCC priming. As shown in Fig.
6, this treatment
completely blocked the enhancement of the PCC-induced IFN-

production
triggered by
T. gondii infection. Although
anti-IL-12 treatment
also appeared to increase the PCC-induced IL-4
production, this
effect was not statistically
significant.
 |
DISCUSSION |
T. gondii is an unusual protozoan in its ability to
potentiate strong cell-mediated immune responses. This property, which protects the host against mortality while promoting dormant cyst formation, may have evolved as a mechanism for ensuring parasite persistence. Indeed, the activation of the cellular immune system induced by T. gondii is so potent that it can lead to
nonspecific resistance against other pathogens (13, 16) as
well as both autochthonous and transplantable tumors (8).
Although the nature of the host-parasite interactions that determine
the immunopotentiating properties of the protozoan are not yet defined,
they are likely to relate to its ability to stimulate high levels of
host protective cytokines such as IFN-
(3). The induction
of IL-12 by tachyzoite products appears to be an important upstream
event in this process and may promote IFN-
-dependent resistance by
both the innate and adaptive arms of the immune system (23).
At a different level, the strong cell-mediated immunity induced by
T. gondii might result from a direct effect of the parasite on T-cell responses. For example, tachyzoites as well as tachyzoite extract have been shown to nonspecifically induce in vitro
proliferation of murine CD8+ as well as human
CD4+ cells from uninfected hosts. In the case of the murine
cells, this appears to be due to a superantigen-like activity in the parasite which preferentially expands CD8+ cells expressing
V
5 (2), while with human cells the relevant activity
requires Ag processing and does not appear to involve preferential TCR
usage (22).
In the present study, we have used an in vivo approach to examine
possible nonspecific effects of T. gondii infection on T lymphocytes and, in particular, CD4+ T-cell function. Since
previous studies in
c KO animals had suggested that
CD4+ lymphocytes can mediate early resistance to ME49
infection in the absence of NK and CD8+ T cells
(17), we initially focused on the question of whether or not
transgenic T cells expressing an unrelated TCR could be triggered to
act as IFN-
-producing effectors. Our results clearly indicate that
these CD4+ cells neither secrete IFN-
in response to in
vivo T. gondii infection nor function as effectors of acute
resistance against the parasite. This finding argues that the
IFN-
-producing CD4+ T lymphocytes previously detected
during early infection (6) arise as a result of conventional
TCR ligation. A further implication of our results is that the early
control of parasite growth by CD4+ T lymphocytes observed
previously in
c KO mice is likely to result from an
Ag-specific encounter and may be particularly effective because the
cells have an activated memory phenotype (15).
Although B10.A PCC TCR transgenic mice were similar to B10.A
Rag-2
/
animals in their resistance to infection,
surprisingly, WT B10.A mice from the same Taconic colony failed to
display the long-term survival predicted from their
H-2a haplotype. Nevertheless, it was clear from
the cyst counts performed on the same animals that they completely
controlled parasite growth and in that sense were comparable to B10.A
mice from the Jackson Laboratory which exhibited the predicted
phenotype of prolonged survival (Fig. 3). Thus, despite this unexpected
complication, one can be confident that the PCC transgenic mice indeed
fail to display the parasite control shown by their WT B10.A
counterparts. Although the basis of the premature mortality of the
Taconic-derived B10.A mice is presently unclear, a preliminary analysis
(C. M. Collazo and C. Anderson, unpublished findings) suggests
that it is not the result of a detectable major or minor
histocompatibility difference as determined by skin grafting. Other
possible explanations include non-histocompatibility-related genetic
changes or differences in the intestinal flora between the two mouse colonies.
While the results of the first part of this study indicated that
T. gondii infection fails to nonspecifically activate
CD4+ T lymphocytes to become IFN-
-dependent effectors,
it was still possible that the parasite influences the development and
phenotype of CD4+ T cells responding as a result of TCR
ligation. This possibility was tested by assaying the effect of ME49
infection on PCC-induced T-cell responses in transgenic mice. Using a
protocol in which mice were exposed to T. gondii for 5 d before PCC injection, we failed to detect any effect of the infection
on CD69 and CD44 expression by transgenic CD4+ T cells
either in the presence or in the absence of in vivo Ag priming (Fig.
5). Thus, at least in terms of these prototypic markers, the parasite
does not appear to dramatically affect the initial activation status of
the T cells. Therefore, the immunostimulatory activity of T. gondii cannot be readily attributed to a nonspecific effect on
CD4+ T-cell activation per se. An alternative explanation
of this immunostimulatory function, for which we know of no precedent, is that lymphokines or other products of T. gondii-specific
T lymphocytes nonspecifically activate bystander CD4+ T cells.
One striking immunological feature of Toxoplasma infection
is the Th1-biased cytokine expression pattern that it induces (reviewed in reference 3). Although not as yet formally
defined at the single-cell level, this pattern is likely to result from
the skewing of lymphokine production by CD4+ as well as
CD8+ and NK cells. The results presented here establish
that T. gondii infection strongly biases PCC- and
alum-stimulated CD4+ T-cell responses, which normally
display a Th0 pattern, toward a Th1-dominated profile (Fig. 6). This
potent effect on the development of CD4 type 1 cytokine expression
suggests that the ability of the parasite to nonspecifically promote
Th1 responses is central to its immunostimulatory influence on host
resistance to other agents. In turn, since in vivo anti-IL-12 treatment
prevented the development of an IFN-
-dominated lymphokine response
profile, it would appear that the induction of IL-12 is a critical
event that influences Th1 biasing and could be the basis for the
augmentation of resistance to unrelated pathogens and tumors seen in
T. gondii-infected animals. Because IL-12 itself is
essential for control of parasite growth, it is difficult to design
depletion experiments in which the role of the cytokine in the
generation of this nonspecific resistance can be readily tested.
Nevertheless, in a number of the experimental models in which T. gondii induces nonspecific immunity (e.g., Listeria
monocytogenes [24], Schistosoma
mansoni [26], and Salmonella sp.
[12]) recombinant IL-12 confers or enhances host
control of the secondary infection.
While the above observations argue that IL-12 induction is a critical
factor responsible for the immunopotentiating activity of T. gondii infection, they do not formally rule out the involvement of
other stimulatory effects of the parasite on the immune system. The TCR
transgenic model described here should provide a useful tool for
assessing these additional determinants as well as for studying the
influence of T. gondii on Ag presentation. As a second and
related approach for analyzing the effects of the protozoan on
processing and presentation, we have recently developed transgenic parasites expressing the model Ags ovalbumin and hen egg lysozyme. We
hope that this strategy involving the combined study of transgenic parasites and TCR transgenic mice will allow us to identify the unique
characteristics of the T. gondii-host interaction
responsible for the potent induction of cell-mediated immunity by this pathogen.
 |
ACKNOWLEDGMENTS |
We thank David Stephany and Kevin L. Holmes for their invaluable
advice and assistance in flow cytometry and Dragana Jankovic and Marika
Kullberg for their helpful discussions and criticism.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Bldg. 4, Room
126, National Institutes of Health, 4 Center Dr., Bethesda, MD
20892-0425. Phone: (301) 496-8218. Fax: (301) 402-0890. E-mail:
CCOLLAZO{at}niaid.nih.gov.
Present address: Department of Immunobiology, Guy's, King's, and
St. Thomas' Medical School, London, United Kingdom SE1 9RT.
Editor:
S. H. E. Kaufmann
 |
REFERENCES |
| 1.
|
Brown, C. R., and R. Mcleod.
1990.
Class I MHC genes and CD8+ T Cells determine cyst number in Toxoplasma gondii infection.
J. Immunol.
145:3438-3441[Abstract].
|
| 2.
|
Denkers, E. Y.,
P. Caspar, and A. Sher.
1994.
Toxoplasma gondii possesses a superantigen activity that selectively expands murine T cell receptor V 5-bearing CD8+ lymphocytes.
J. Exp. Med.
180:985-994[Abstract/Free Full Text].
|
| 3.
|
Denkers, E. Y., and R. T. Gazzinelli.
1998.
Regulation and function of T-cell-mediated immunity during Toxoplasma gondii infection.
Clin. Microbiol. Rev.
11:569-588[Abstract/Free Full Text].
|
| 4.
|
Dialynas, D. P.,
D. B. Wilde,
P. Marrack,
A. Pierres,
K. A. Wall,
W. Havran,
G. Otten,
M. R. Loken,
M. Pierres,
J. Kappler, et al.
1983.
Characterization of the murine antigenic determinant, designated L3T4a, recognized by monoclonal antibody GK1.5: expression of L3T4a by functional T cell clones appears to correlate primarily with class II MHC antigen-reactivity.
Immunol. Rev.
74:29-56[CrossRef][Medline].
|
| 5.
|
Gazzinelli, R. T.,
S. Hieny,
T. A. Wynn,
S. Wolf, and A. Sher.
1993.
Interleukin-12 is required for the T-lymphocyte-independent induction of interferon- by an intracellular parasite and induces resistance in T-cell-deficient hosts.
Proc. Natl. Acad. Sci. USA
90:6115-6119[Abstract/Free Full Text].
|
| 6.
|
Gazzinelli, R. T.,
M. Wysocka,
S. Hayashi,
E. Y. Denkers,
S. Hieny,
P. Caspar,
G. Trinchieri, and A. Sher.
1994.
Parasite-induced IL-12 stimulates early IFN- synthesis and resistance during acute infection with Toxoplasma gondii.
J. Immunol.
153:2533-2543[Abstract].
|
| 7.
|
Grunvald, E.,
M. Chiaramonte,
S. Hieny,
M. Wysocka,
G. Trinchieri,
S. N. Vogel,
R. T. Gazzinelli, and A. Sher.
1996.
Biochemical characterization and protein kinase C dependency of monokine-inducing activities of Toxoplasma gondii.
Infect. Immun.
64:2010-2018[Abstract].
|
| 8.
|
Hibbs, J. B. J.,
L. H. Lambert, and J. S. Remington.
1971.
Resistance to murine tumours conferred by chronic infection with intracellular protozoa, Toxoplasma gondii and Besnoitia jellisoni.
J. Infect. Dis.
124:587-592[Medline].
|
| 9.
|
Hunter, C. A.,
C. S. Subauste,
V. H. Van Cleave, and J. S. Remington.
1994.
Production of gamma interferon by natural killer cells from Toxoplasma gondii-infected SCID mice: regulation by interleukin-10, interleukin-12, and tumor necrosis factor alpha.
Infect. Immun.
62:2818-2824[Abstract/Free Full Text].
|
| 10.
|
Hunter, C. A.,
Y. Suzuki,
C. S. Subauste, and J. S. Remington.
1996.
Cells and cytokines in resistance to Toxoplasma gondii.
Curr. Top. Microbiol. Immunol.
219:113-125[Medline].
|
| 11.
|
Jenkins, M. K.,
C. A. Chen,
G. Jung,
D. L. Mueller, and R. H. Schwartz.
1990.
Inhibition of antigen-specific proliferation of type 1 murine T cell clones after stimulation with immobilized anti-CD3 monoclonal antibody.
J. Immunol.
144:16-22[Abstract].
|
| 12.
|
Kincy-Cain, T.,
J. D. Clements, and K. L. Bost.
1996.
Endogenous and exogenous interleukin-12 augment the protective immune response in mice orally challenged with Salmonella dublin.
Infect. Immun.
64:1437-1440[Abstract].
|
| 13.
|
Mahmoud, A. A. F.,
K. S. Warren, and G. T. Strickland.
1976.
Acquired resistance to infection with Schistosoma mansoni induced by Toxoplasma gondii.
Nature
263:56-57[CrossRef][Medline].
|
| 14.
|
Miller, C.,
J. A. Ragheb, and R. H. Schwartz.
1999.
Anergy and cytokine-mediated suppression as distinct superantigen-induced tolerance mechanisms in vivo.
J. Exp. Med.
190:1-12[Abstract/Free Full Text].
|
| 15.
|
Nakajima, H.,
E. W. Shores,
M. Noguchi, and W. J. Leonard.
1997.
The common cytokine receptor chain plays an essential role in regulating lymphoid homeostasis.
J. Exp. Med.
185:189-195[Abstract/Free Full Text].
|
| 16.
|
Ruskin, J., and J. S. Remington.
1968.
Immunity and intracellular infection: resistance to bacteria in mice infected with a protozoan.
Science
160:72-74[Abstract/Free Full Text].
|
| 17.
|
Scharton-Kersten, T.,
H. Nakajima,
G. Yap,
A. Sher, and W. J. Leonard.
1998.
Infection of mice lacking the common cytokine receptor gamma-chain ( c) reveals an unexpected role for CD4+ T lymphocytes in early IFN- -dependent resistance to Toxoplasma gondii.
J. Immunol.
160:2565-2569[Abstract/Free Full Text].
|
| 18.
|
Scharton-Kersten, T. M.,
T. A. Wynn,
E. Y. Denkers,
S. Bala,
E. Grunvald,
S. Hieny,
R. T. Gazzinelli, and A. Sher.
1996.
In the absence of endogenous IFN- , mice develop unimpaired IL-12 responses to Toxoplasma gondii while failing to control acute infection.
J. Immunol.
157:4045-4054[Abstract].
|
| 19.
|
Scott, P.,
P. Natovitz,
R. L. Coffman,
E. Pearce, and A. Sher.
1988.
Immunoregulation of cutaneous leishmaniasis. T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens.
J. Exp. Med.
168:1675-1684[Abstract/Free Full Text].
|
| 20.
|
Seder, R. A.,
W. E. Paul,
M. M. Davis, and B. Fazekas De St. Groth.
1992.
The presence of interleukin-4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T cell receptor transgenic mice.
J. Exp. Med.
176:1091-1098[Abstract/Free Full Text].
|
| 21.
|
Su, H. C.,
L. P. Cousens,
L. D. Fast,
M. K. Slifka,
R. D. Bungiro,
R. Ahmed, and C. A. Biron.
1998.
CD4+ and CD8+ T cell interactions in IFN- and IL-4 responses to viral infections: requirements for IL-2.
J. Immunol.
160:5007-5017[Abstract/Free Full Text].
|
| 22.
|
Subauste, C. S.,
F. Fuh,
R. De Waal Malefyt, and J. S. Remington.
1998.
Alpha beta T cell response to Toxoplasma gondii in previously unexposed individuals.
J. Immunol.
160:3403-3411[Abstract/Free Full Text].
|
| 23.
|
Trinchieri, G.
1995.
Interleukin-12: a proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity.
Annu. Rev. Immunol.
13:251-276[Medline].
|
| 24.
|
Wagner, R. D.,
H. Steinberg,
J. F. Brown, and C. J. Czuprynski.
1994.
Recombinant interleukin-12 enhances resistance of mice to Listeria monocytogenes infection.
Microb. Pathog.
17:175-186[CrossRef][Medline].
|
| 25.
|
Wu, C. Y.,
C. Demeure,
M. Kiniwa,
M. Gately, and G. Delespesse.
1993.
IL-12 induces the production of IFN- by neonatal human CD4 T cells.
J. Immunol.
151:1938-1949[Abstract].
|
| 26.
|
Wynn, T. A.,
A. Reynolds,
S. James,
A. W. Cheever,
P. Caspar,
S. Hieny,
D. Jankovic,
M. Strand, and A. Sher.
1996.
IL-12 enhances vaccine-induced immunity to schistosomes by augmenting both humoral and cell-mediated immune responses against the parasite.
J. Immunol.
157:4068-4078[Abstract].
|
Infection and Immunity, May 2000, p. 2713-2719, Vol. 68, No. 5
0019-9567/00/$04.00+0